Skip to main content
News > News > Ronald Laymon, PhD, JD, Appointed To Bacterial Robotics Science Directorate

Ronald Laymon, PhD, JD, Appointed To Bacterial Robotics Science Directorate

Dr. Laymon will advise on scientifically-based intellectual property and complex licensing transactions.

CINCINNATI, OH. – November 18, 2013 – Bacterial Robotics is a life science biotechnology firm.  The Company uses synthetic biology tools in an evolutionary engineering approach to develop bacterial robots, or BactoBots.  Today, the Company announced the appointment of Dr. Ron Laymon to its Scientific Directorate.

With the development and response to the Company’s initial BactoBot intellectual property transaction, it became evident there would be significant and beneficial scientific, legal and social consequences to its licensing business model.  Dr. Laymon’s expertise will influence the Company’s development and presentation of its intellectual properties into its unique licensing business model.  Dr. Laymon is an emeritus Philosophy of Science Professor and was also, as a second career, an attorney whose practice was primarily commercial litigation with a major law firm.

Jason E. Barkeloo, CEO stated, “We are fortunate. Ron was involved in several major commercial litigations and contributed to nearly a dozen United States Supreme Court Briefs.  He is also widely recognized for his philosophical work in the analysis of scientific argumentation and experimentation.  That he chose our firm as the only Company to ally his passion and knowledge speaks to our team, intellectual property efforts, and focus on generating value.”

For his part, Dr. Laymon stated that he is “very pleased to be able to offer his assistance in the development of what will assuredly be a very exciting and comprehensive line of products.”

Barkeloo finished, “We are focused upon creating intellectual property and partnering with licensees to commercialize our innovations.  Dr. Laymon is a rare leader.  His domain expertise in both science and global corporate law will establish a potent product development culture inside Bacterial Robotics.  Our licensees and investors will benefit from his leadership.”

More on Dr. Laymon is at: http://bacterialrobotics.com/about/science-directorate/

About Bacterial Robotics

An early developer in the emerging synthetic biology industry, Bacterial Robotics is headquartered in Cincinnati, Ohio (USA).  The Company specializes in identifying markets for developing and deploying BactoBots™ and ViruBots™; microscopic organism-based robots that produce, build, sense, and perform functions.

The Company’s products are protected by a proprietary genetics rights management (GeRM™) key system.  The GeRM system is a consumable additive that prevents the BactoBots against theft or environmental release.  GeRM enables the Company to gain licensing revenues from the manufacture and distribution of its BactoBots.

Once Bacterial Robotics develops a BactoBot, it creates a go-to-market subsidiary to launch the product.  Pilus Energy is the Company’s first subsidiary deploying the RemediBot™ that cleans industrial wastewater.  Pilus Energy is also also licensing the wastewater-to-value GalvaniBot™ to clean wastewater, produce economically important chemicals, and generate direct current electricity.

For more information on Bacterial Robotics, visit its web site at http://BacterialRobotics.com

VIEW .PDF

Contact 
Jason E. Barkeloo – CEO
+1.513.252.2901
Twitter:  @BactoBot at http://twitter.com/BactoBot
http://BacterialRobotics.com/contact/
info(at)BacterialRobotics.com

Our Effort

Open Therapeutics is a major backer of open science and open access efforts.

Open Therapeutics freely provides to science, technology, engineering, and math (STEM) scientists, or another other seriously interested persons, intellectual properties (patents, etc.), grant funding, lab equipment, document development tools, and preprint server in a collaboration platform (Therapoid™).

When the researchers advance the intellectual properties, s/he gains ScienceCoins™; a blockchain-based cryptocurrency.